June 28, 2019 10:32 AM EDT

MiMedx is in trouble, again; Pfizer's Avastin biosimilar wins FDA approval

Natalie Grover

Reporter

→ The controversial MiMedx has dug itself a deeper hole. Senior officials at the wound care company, which has long been criticized for its business …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

MiMedx is in trouble, again; Pfizer's Avastin biosimilar wins FDA approval

Natalie Grover

Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

MiMedx is in trou­ble, again; Pfiz­er's Avastin biosim­i­lar wins FDA ap­proval

Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

MiMedx is in trouble, again; Pfizer's Avastin biosimilar wins FDA approval